On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having high expressions of PD-L1 (>50%) and no changes in EGFR or ALK. The FDA based their approval on the results of the clinical trial IMpower-110 which showed that patients receiving Tecentriq (atezolizumab) lived longer, had a higher chance of responding well to treatment, and went longer periods of time without progression than those receiving chemotherapy.

Tecentriq (atezolizumab) being available as a first line immunotherapy option for NSCLC gives patients more options for first line treatments than ever before.

Click here to read the full press release.